Decentralized sleep studies — remote, virtual, and hybrid designs that move data collection to the patient's home — are becoming the default rather than the exception. When designed well, they cut enrollment timelines by 30-50%, expand the eligible population beyond patients who live near an academic sleep lab, and produce regulatory-grade data.
What can be decentralized today
- OSA screening and titration — validated HSAT devices ship directly to participants.
- Insomnia trials — actigraphy, e-diaries, and validated ePROs (ISI, PSQI) via smartphone.
- Adherence monitoring — PAP device telemetry, connected pill bottles, digital therapeutic engagement logs.
- Circadian assays — home DLMO saliva sampling with light-exposure actigraphy.
What still belongs in a lab
The MSLT and MWT for narcolepsy programs, high-density EEG for neurological co-registration, and any protocol requiring simultaneous CO2 monitoring should stay in-lab. Hybrid designs — in-lab PSG at baseline and end-of-treatment, HSAT and actigraphy in between — combine the best of both worlds.
Wearables as endpoint sources
FDA has cleared several consumer-grade wearables (Apple Watch, Fitbit, WHOOP, Oura) for specific sleep and heart-rhythm indications. Sponsors incorporating wearable data as a primary or secondary endpoint should read our wearable clinical trials guide for validation and Part 11 considerations.
Operational risks to plan for
- Device deployment logistics — chain of custody, cleaning, replacement inventory.
- Data quality — invalid HSAT rates run 8-15%; budget re-tests into the protocol.
- Participant support — 24/7 device troubleshooting line, video visit capacity for coaching.
Our sleep research CRO practice runs fully decentralized, hybrid, and traditional in-lab sleep studies; our digital health CRO team owns the software validation and connected-device data pipeline.